Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Guggenheim Keeps Their Buy Rating on Adicet Bio (ACET)

Tipranks - Tipranks - Sun Mar 15, 11:30AM CDT

Guggenheim analyst Yatin Suneja maintained a Buy rating on Adicet Bio yesterday and set a price target of $100.00. The company’s shares closed yesterday at $7.21.

Claim 70% Off TipRanks Premium

According to TipRanks, Suneja is a 5-star analyst with an average return of 29.2% and a 56.68% success rate. Suneja covers the Healthcare sector, focusing on stocks such as Dianthus Therapeutics, Roivant Sciences, and DBV Technologies SA – American.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adicet Bio with a $42.60 average price target, representing a 490.85% upside. In a report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $25.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Adicet Bio’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $30.52 million. In comparison, last year the company had a GAAP net loss of $28.73 million

Read More on ACET:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).